Savings From Interchangeable Biosimilars May Be Muted
October
28
The month of October brought two important developments for interchangeable biosimilars, which industry observers have long hoped will help increase uptake of lower-cost versions of complex biologic drugs.
On Oct. 15, the FDA approved Cyltezo, the first interchangeable biosimilar version of blockbuster autoimmune condition treatment Humira. And on Oct. 20, Cigna Corp.-owned Express Scripts revealed that it will now prefer Semglee — the first FDA-approved interchangeable biosimilar on the U.S. market — over the branded long-acting insulin Lantus on the PBM’s largest formulary.
© 2022 MMIT
Meet Our Reporters
-
Angela Maas Managing Editor, RADAR on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and RADAR on Drug Benefits
View Leslie Small's Profile -
Lauren Flynn Kelly Managing Editor, RADAR on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Peter Johnson Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, RADAR on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Jinghong Chen's Profile -
Jill Brown Kettler Executive Editor
View Jill Brown Kettler's Profile